Notable amongst these differences were that the TN-BCs expressed more TNF-α and its receptor, TNFR1, than ER-positive BCs, and that the TN-BCs expressed less of the death-inducing components of the TNF/TNFR1 pathway, specifically caspase-3 and -8, FADD, RIPK1, and RIPK3, compared with ER-positive BC. This evidence concerns the gene RIPK1 and breast cancer.